Limits...
Percutaneous ablation therapies of inoperable pancreatic cancer: a systematic review.

Ierardi AM, Lucchina N, Bacuzzi A, Marco de C, Bracchi E, Cocozza E, Dionigi G, Tsetis D, Floridi C, Carrafiello G - Ann Gastroenterol (2015 Oct-Dec)

Bottom Line: Initial studies about ablation therapies of the pancreas were associated with significant morbidity and mortality, which limited widespread adoption.Development of techniques with high quality imaging used as guidance improve outcomes reducing complications.They are performed by very skilled operators in highly specialized centers.

View Article: PubMed Central - PubMed

Affiliation: Interventional Radiology Unit, Department of Radiology (Anna Maria Ierardi, Natalie Lucchina, De Chiara Marco, Elena Bracchi, Gianpaolo Carrafiello), University of Insubria, Varese, Italy.

ABSTRACT
Initial studies about ablation therapies of the pancreas were associated with significant morbidity and mortality, which limited widespread adoption. Development of techniques with high quality imaging used as guidance improve outcomes reducing complications. Moreover, only few experiences of percutaneous pancreatic ablations are reported. They are performed by very skilled operators in highly specialized centers. This review presents the current status of percutaneous local ablative therapies in the treatment of advanced pancreatic cancer.

No MeSH data available.


Related in: MedlinePlus

(A) Contrast-enhanced computed tomography reveals the presence of the pancreatic tumor. (B) maximum intensity projection (MIP) reconstruction demonstrates the presence of 5-needle for irreversible electroporation
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4585388&req=5

Figure 2: (A) Contrast-enhanced computed tomography reveals the presence of the pancreatic tumor. (B) maximum intensity projection (MIP) reconstruction demonstrates the presence of 5-needle for irreversible electroporation

Mentions: Four studies (Table 4), involving a total of 21 patients with locally advanced ductal adenocarcinoma treated with percutaneous IRE were analyzed [19,27-29] (Fig. 2 A, B). There were 1 prospective study, 2 retrospective studies, and 1 case report. Narayanan [30] added another 4 patients reported in a very recent study which contained data related to vascular patency post IRE in different organs and in particular 18 pancreatic carcinomas (14 published in 2012 [19] and 4 performed in the last years and reported in this recent study). Efficacy was not among the aims of his recent study, and dimensions, locations, histology, complications, follow up, and response were not reported. Recently, Scheffer et al [31] reported a case of percutaneous pancreatic IRE: they reported the feasibility and the safety of the dorsal approach. They did not report data on the follow up and we excluded this case from our study.


Percutaneous ablation therapies of inoperable pancreatic cancer: a systematic review.

Ierardi AM, Lucchina N, Bacuzzi A, Marco de C, Bracchi E, Cocozza E, Dionigi G, Tsetis D, Floridi C, Carrafiello G - Ann Gastroenterol (2015 Oct-Dec)

(A) Contrast-enhanced computed tomography reveals the presence of the pancreatic tumor. (B) maximum intensity projection (MIP) reconstruction demonstrates the presence of 5-needle for irreversible electroporation
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4585388&req=5

Figure 2: (A) Contrast-enhanced computed tomography reveals the presence of the pancreatic tumor. (B) maximum intensity projection (MIP) reconstruction demonstrates the presence of 5-needle for irreversible electroporation
Mentions: Four studies (Table 4), involving a total of 21 patients with locally advanced ductal adenocarcinoma treated with percutaneous IRE were analyzed [19,27-29] (Fig. 2 A, B). There were 1 prospective study, 2 retrospective studies, and 1 case report. Narayanan [30] added another 4 patients reported in a very recent study which contained data related to vascular patency post IRE in different organs and in particular 18 pancreatic carcinomas (14 published in 2012 [19] and 4 performed in the last years and reported in this recent study). Efficacy was not among the aims of his recent study, and dimensions, locations, histology, complications, follow up, and response were not reported. Recently, Scheffer et al [31] reported a case of percutaneous pancreatic IRE: they reported the feasibility and the safety of the dorsal approach. They did not report data on the follow up and we excluded this case from our study.

Bottom Line: Initial studies about ablation therapies of the pancreas were associated with significant morbidity and mortality, which limited widespread adoption.Development of techniques with high quality imaging used as guidance improve outcomes reducing complications.They are performed by very skilled operators in highly specialized centers.

View Article: PubMed Central - PubMed

Affiliation: Interventional Radiology Unit, Department of Radiology (Anna Maria Ierardi, Natalie Lucchina, De Chiara Marco, Elena Bracchi, Gianpaolo Carrafiello), University of Insubria, Varese, Italy.

ABSTRACT
Initial studies about ablation therapies of the pancreas were associated with significant morbidity and mortality, which limited widespread adoption. Development of techniques with high quality imaging used as guidance improve outcomes reducing complications. Moreover, only few experiences of percutaneous pancreatic ablations are reported. They are performed by very skilled operators in highly specialized centers. This review presents the current status of percutaneous local ablative therapies in the treatment of advanced pancreatic cancer.

No MeSH data available.


Related in: MedlinePlus